B. Gazzard

B. Gazzard, R. Davey, M. Saag, 2008, Journal of interferon & cytokine research : the official journal of the International Society for Interferon and Cytokine Research.

Causes of Weight Loss in Human Immunodeficiency Virus Infection

B. Gazzard, C. Summerbell, J. Perrett, 1993, International journal of STD & AIDS.

Early changes in coagulation following a paracetamol overdose and a controlled trial of fresh frozen plasma therapy.

B. Gazzard, J. Henderson, R. Williams, 1975, Gut.

Disorderd hemostasis in liver damage from paracetamol overdose.

B. Gazzard, R. Williams, K. Shilkin, 1973, Gastroenterology.

1998 revision to the British HIV Association guidelines for antiretroviral treatment of HIV seropositive individuals

B. Gazzard, G. Graeme, 1998, The Lancet.

Factor VIII levels during the course of acute hepatitis in a haemophiliac.

B. Gazzard, R. Williams, P. Flute, 1975, Journal of clinical pathology.

haemophiliac . course of acute hepatitis in a Factor VIII levels during the

B. Gazzard, Roger Williams, P. Flute, 2022 .

A controlled trial of heparin therapy in the coagulation defect of paracetamol-induced hepatic necrosis

B. Gazzard, R. Williams, R. Clark, 1974, Gut.

Non-cryptosporidial diarrhoea in human immunodeficiency virus (HIV) infected patients.

B. Gazzard, D. Hawkins, D. Shanson, 1989, Gut.

Human BDCA-1-Positive Blood Dendritic Cells Differentiate into Phenotypically Distinct Immature and Mature Populations in the Absence of Exogenous Maturational Stimuli: Differentiation Failure in HIV Infection1

B. Gazzard, P. Amjadi, P. Kelleher, 2005, The Journal of Immunology.

InfectionStimuli: Differentiation Failure in HIV the Absence of Exogenous Maturational Distinct Immature and Mature Populations in Cells Differentiate into Phenotypically Human BDCA-1-Positive Blood Dendritic

B. Gazzard, P. Amjadi, P. Kelleher, 2005 .

Dysfunction and infection of freshly isolated blood myeloid and plasmacytoid dendritic cells in patients infected with HIV-1.

B. Gazzard, F. Gotch, S. Patterson, 2003, Blood.

Pre-exposure prophylaxis to prevent the acquisition of HIV-1 infection (PROUD): effectiveness results from the pilot phase of a pragmatic open-label randomised trial

Sheena McCormack, Anne M Johnson, Christine Bowman, 2016, The Lancet.

Charcoal haemoperfusion for paracetamol overdose.

B. Gazzard, R. Willison, R. P. Thompson, 1974, British journal of clinical pharmacology.

Antiretroviral treatment for adult HIV infection in 2002: updated recommendations of the International AIDS Society-USA Panel.

Michael S Saag, Mauro Schechter, Paul A Volberding, 2002, JAMA.

Advances in sexually transmitted infections of the gastrointestinal tract

S. Ng, B. Gazzard, S. Ng, 2009, Nature Reviews Gastroenterology &Hepatology.

Tenofovir DF, emtricitabine, and efavirenz vs. zidovudine, lamivudine, and efavirenz for HIV.

Joel E Gallant, Edwin DeJesus, B. Gazzard, 2006, The New England journal of medicine.

Are HIV-infected patients with rapid CD4 cell decline a subgroup who benefit from early antiretroviral therapy?

B. Gazzard, P. Easterbrook, D. Cooper, 1999, The Journal of antimicrobial chemotherapy.

Summary of the II International Symposium on Cytomegalovirus.

B. Gazzard, P. Griffiths, S. Spector, 1998, Antiviral research.

Influence of atazanavir 200 mg on the intracellular and plasma pharmacokinetics of saquinavir and ritonavir 1600/100 mg administered once daily in HIV-infected patients.

B. Gazzard, S. Khoo, J. Ford, 2006, The Journal of antimicrobial chemotherapy.

Intracellular and Plasma Pharmacokinetics of Saquinavir-Ritonavir, Administered at 1,600/100 Milligrams Once Daily in Human Immunodeficiency Virus-Infected Patients

B. Gazzard, S. Khoo, J. Ford, 2004, Antimicrobial Agents and Chemotherapy.

Histoplasmosis in a UK patient treated with itraconazole.

B. Gazzard, M. Youle, M. Nelson, 1990, AIDS (London).

Itraconazole versus ketaconazole in the treatment of oral and oesophageal candidosis in patients infected with HIV.

B. Gazzard, D. Smith, Don E. Smith, 1991, AIDS.

Treatment with corticosteroids— a risk factor for the development of clinical cytomegalovirus disease in AIDS

B. Gazzard, D. Hawkins, M. Nelson, 1993, AIDS.

Oesophageal symptoms, their causes, treatment, and prognosis in patients with the acquired immunodeficiency syndrome.

B. Gazzard, D. Hawkins, O. Husain, 1989, Gut.

The changing pattern of AIDS-defining illnesses with the introduction of highly active antiretroviral therapy (HAART)in a London clinic.

B. Gazzard, P. Easterbrook, N. Ives, 2001, The Journal of infection.

Diagnosis, treatment and outcome of pneumonia in the acquired immune deficiency syndrome.

B. Gazzard, M. Youle, P. Griffiths, 1989, The Journal of infection.

Unresponsive HIV-related oro-oesophageal candidosis--an evaluation of two new in-vitro azole susceptibility tests.

B. Gazzard, M. Petrou, D. Shanson, 1997, The Journal of antimicrobial chemotherapy.

The incidence of AIDS-defining illnesses at a current CD4 count ≥ 200 cells/μL in the post-combination antiretroviral therapy era.

B. Gazzard, A. Mocroft, O. Kirk, 2013, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

CD4 Cell Count and the Risk of AIDS or Death in HIV-Infected Adults on Combination Antiretroviral Therapy with a Suppressed Viral Load: A Longitudinal Cohort Study from COHERE

B. Gazzard, O. Kirk, H. Furrer, 2012, PLoS medicine.

Late diagnosis in the HAART era: proposed common definitions and associations with mortality

B. Gazzard, C. Leen, C. Sabin, 2010, AIDS.

Fever in the recently returned HIV infected traveller

B. Gazzard, R. Miller, A. Dogan, 2004, Sexually Transmitted Infections.

Quantitative and qualitative comparison of DNA amplification by PCR with immunofluorescence staining for diagnosis of Pneumocystis carinii pneumonia.

B. Gazzard, J. Collins, T. Leigh, 1993, Journal of clinical pathology.

1 Clinical picture and management

B. Gazzard, 1990 .

Fibreoptic bronchoscopy in diagnosis of bronchopulmonary Kaposi's sarcoma.

B. Gazzard, P. Hanson, J. Collins, 1987, Thorax.

The acquired immune deficiency syndrome: problems associated with the management of Pneumocystis carinii pneumonia.

B. Gazzard, C. Farthing, D. Shanson, 1985, The Journal of infection.

Pneumocystis carinii pneumonia treated with eflornithine in AIDS patients resistant to conventional therapy.

B. Gazzard, M. Youle, D. Smith, 1990, AIDS.

Where does HIV live?

B. Gazzard, D. Douek, J. Stebbing, 2004, The New England journal of medicine.

Natural history of AIDS related sclerosing cholangitis: a study of 20 cases.

A. Forbes, B. Gazzard, C. Blanshard, 1993, Gut.

Adenovirus infection of the large bowel in HIV positive patients.

B. Gazzard, J. Moss, N. Francis, 1992, Journal of clinical pathology.

Indicator disease‐guided testing for HIV – the next step for Europe?

B. Gazzard, A. d’Arminio Monforte, J. Lundgren, 2008, HIV medicine.

Pilot studies of azithromycin, letrazuril and paromomycin in the treatment of cryptosporidiosis

B. Gazzard, D. Shanson, C. Blanshard, 1997, International journal of STD & AIDS.

Gastrointestinal manifestations of HIV infection

B. Gazzard, D. Sharpstone, 1996, The Lancet.

Natural history and prognosis of diarrhoea of unknown cause in patients with acquired immunodeficiency syndrome (AIDS).

B. Gazzard, C. Blanshard, 1995, Gut.

Cryptosporidiosis in HIV-seropositive patients.

B. Gazzard, D. Shanson, N. Francis, 1992, The Quarterly journal of medicine.

The significance of the detection of cytomegalovirus in the bronchoalveolar lavage fluid in AIDS patients with pneumonia.

B. Gazzard, M. Youle, D. Smith, 1990, AIDS.

Itraconazole cyclodextrin solution--effective treatment for HIV-related candidosis unresponsive to other azole therapy.

B. Gazzard, M. Youle, J. Midgley, 1994, The Journal of antimicrobial chemotherapy.

Treatment of HIV‐related fluconazole‐resistant oral candidosis with D0870, a new triazole antifungal

B. Gazzard, D. Hawkins, D. Denning, 1998, AIDS.

A dose comparison study of a new triazole antifungal (D0870) in HIV‐positive patients with oral candidiasis

B. Gazzard, D. Hawkins, D. Denning, 1997, AIDS.

Itraconazole cyclodextrin solution: the role of in vitro susceptibility testing in predicting successful treatment of HIV‐related fluconazole‐resistant and fluconazole‐susceptible oral candidosis

B. Gazzard, J. Midgley, J. Cartledge, 1997, AIDS.

The role of azoles in the treatment and prophylaxis of cryptococcal disease in HIV infection

B. Gazzard, M. Fisher, M. Nelson, 1994, AIDS.

Treatment of cryptococcosis with liposomal amphotericin B (AmBisome) in 23 patients with AIDS

Richard J. Coker, B. Gazzard, R. Coker, 1993, AIDS.

Practical advice for the gastroenterologist dealing with symptomatic HIV disease.

B. Gazzard, 1990, Gut.

AIDS: an overview.

B. Gazzard, 1990, Bailliere's clinical gastroenterology.

Investigation of upper gastrointestinal symptoms in patients with AIDS.

A. Forbes, B. Gazzard, J. Gleeson, 1989, AIDS.

The incidence of AIDS-defining illnesses in 4883 patients with human immunodeficiency virus infection

B. Gazzard, P. Easterbrook, A. Phillips, 1998 .

Relationship between untimed plasma lopinavir concentrations and virological outcome on second-line antiretroviral therapy

B. Gazzard, D. Cooper, J. Amin, 2018, AIDS.

Cessation of secondary prophylaxis in patients with cryptococcosis.

B. Gazzard, M. Fisher, N. Nwokolo, 2000, AIDS.

Pilot study of a new triazole derivative (D0870) in HIV patients with oral candidiasis

B. Gazzard, D. Hawkins, D. Denning, 1994 .

Small intestinal transit, absorption, and permeability in patients with AIDS with and without diarrhoea

B. Gazzard, D. Sharpstone, P. Neild, 1999, Gut.

patients with candidosis . acquired immunodeficiency syndrome rates than the capsule formulation in concentrations and better clinical response Itraconazole solution : higher serum drug

B. Gazzard, J. Cartledge, J. Midgely, 2022 .

Oral candidosis in HIV-infected patients.

B. Gazzard, D. Smith, D. Smith, 1990, British journal of clinical practice. Supplement.

Treatment of intestinal microsporidiosis with albendazole in patients with AIDS

B. Gazzard, D. Tovey, D. Ellis, 1992, AIDS.

4 Gastrointestinal opportunistic infections

B. Gazzard, N. Beeching, R. Jones, 2011, HIV Medicine.

Gut Infection in HIV: Past, Present and Future

B. Gazzard, J. Stebbing, S. Portsmouth, 2003 .

Simultaneous infection with two types of intestinal microsporidia in a patient with AIDS.

B. Gazzard, C. Peacock, E. Canning, 1992, Gut.

Histological diagnosis of intestinal microsporidiosis in patients with AIDS.

B. Gazzard, C. Peacock, D. Tovey, 1991, Journal of clinical pathology.

Microsporidiosis in HIV-1-infected individuals

B. Gazzard, C. Blanshard, 1991, The Lancet.

Reversible renal failure caused by a microsporidian infection

B. Gazzard, E. Canning, D. Woodrow, 1994, AIDS.

Electron microscopic changes in Enterocytozoon bieneusi following treatment with albendazole.

B. Gazzard, D. Ellis, G. Tovey, 1993, Journal of clinical pathology.

Eradication of Cryptosporidia and Microsporidia Following Successful Antiretroviral Therapy

B. Gazzard, A. Müller, P. Hayes, 2000, Journal of acquired immune deficiency syndromes.

Case report: pneumatosis intestinalis occurring in association with cryptosporidiosis and HIV infection.

B. Gazzard, C. D. Collins, J. Gleeson, 1992, Clinical Radiology.

Vitreous fluid sampling and viral genome detection for the diagnosis of viral retinitis in patients with AIDS

B. Gazzard, J. Fox, R. Tedder, 1994, Journal of medical virology.

Vitreous fluid sampling and viral genome detection for the diagnosis of viral retinitis in patients with AIDS

B. Gazzard, J. Fox, R. Tedder, 1994 .

Summary of the II international consensus symposium on combined antiviral therapy and implications for future therapies

D. Richman, B. Gazzard, J. Montaner, 1997, Antiviral Research.

Controlled trial of cimetidine for symptomatic treatment of duodenal ulcers.

B. Gazzard, P. Lance, 1983, British medical journal.

Anti-CD4 autoantibodies and screening for anti-idiotypic antibodies to anti-CD4 monoclonal antibodies in HIV-seropositive people.

B. Gazzard, J. Habeshaw, M. Youle, 1990, AIDS.

Faecal alpha 1 antitrypsin as a marker of gastrointestinal disease in HIV antibody positive individuals.

B. Gazzard, D. Sharpstone, M. Nelson, 1996, Gut.

Comparison of first-line antiretroviral therapy with regimens including nevirapine, efavirenz, or both drugs, plus stavudine and lamivudine: a randomised open-label trial, the 2NN Study

B. Gazzard, C. Katlama, K. Ruxrungtham, 2004, The Lancet.

Eradication of cryptosporidia and microsporidia following successful antiretroviral therapy.

B. Gazzard, A. Müller, P. Hayes, 2000 .

Investigation of chronic diarrhoea in acquired immunodeficiency syndrome. A prospective study of 155 patients.

B. Gazzard, N. Francis, C. Blanshard, 1996, Gut.

The treatment of microsporidial diarrhoea with thalidomide.

B. Gazzard, D. Sharpstone, A. Rowbottom, 1995, AIDS.

PCR-ELISA: a new simplified tool for tracing the source of cryptosporidiosis in HIV-positive patients

B. Gazzard, D. Casemore, C. Ong, 2001, Parasitology Research.

Jejunal water and electrolyte transport in human cryptosporidiosis

A. Forbes, B. Gazzard, A. Thillainayagam, 1996, Digestive Diseases and Sciences.

Jejunal Water Electrolyte Transport Human Cryptosporidiosis in

A. Forbes, B. Gazzard, A. Thillainayagam, 1996 .

Histological diagnosis ofintestinal microsporidiosis inpatients withAIDS

B. Gazzard, D. SEllis, 1991 .

Kingella kingae septicaemia with a clinical presentation resembling disseminated gonococcal infection.

B. Gazzard, D. Shanson, 1984, British medical journal.

Radiological and pathological features of AIDS-related polypoid cholangitis.

A. Forbes, B. Gazzard, C. D. Collins, 1993, Clinical radiology.

Correlation between markers of strain variation in Cryptosporidium parvum: Evidence of clonality

B. Gazzard, M. Ibrahim, C. Ong, 1998 .

Herpes simplex type 1 encephalitis in acquired immunodeficiency syndrome

B. Gazzard, F. Scaravilli, R. Guiloff, 1993, Annals of neurology.

Controlled trial of cysteamine and dimercaprol after paracetamol overdose.

J. R. Bennet, B. Gazzard, R. Hughes, 1977, British medical journal.

Highly active anti-retroviral therapy (HAART) prolongs time to treatment failure in Kaposi's sarcoma.

B. Gazzard, K. Fife, M. Nelson, 1999, AIDS.

Cryptosporidiosis: eradication or suppression with combination antiretroviral therapy?

B. Gazzard, F. M. Awad-El-Kariem, Y. Miao, 1999, AIDS.

Diclazuril in the treatment of severe cryptosporidial diarrhoea in AIDS patients.

B. Gazzard, M. Youle, G. M. Connolly, 1990, AIDS.

Cryptosporidial diarrhoea in AIDS and its treatment.

London, B. Gazzard, D. Shanson, 1988, Gut.

Toxic megacolon in cryptosporidiosis.

B. Gazzard, G. M. Connolly, 1987, Postgraduate medical journal.

Dolutegravir plus lamivudine versus dolutegravir plus tenofovir disoproxil fumarate and emtricitabine in antiretroviral-naive adults with HIV-1 infection (GEMINI-1 and GEMINI-2): week 48 results from two multicentre, double-blind, randomised, non-inferiority, phase 3 trials

B. Gazzard, K. Tashima, M. Shields, 2019, The Lancet.

Effects of haemoperfusion through charcoal or XAD-2 resin on an animal model of fulminant liver failure

B. Gazzard, R. Williams, M. Weston, 1974, Gut.

Prognostic value of serum alpha-fetoprotein in fulminant hepatic failure including patients treated by charcoal haemoperfusion.

B. Gazzard, R. Williams, I. Murray-Lyon, 1976, Gut.

Early and nonreversible decrease of CD161++ /MAIT cells in HIV infection.

B. Gazzard, P. Klenerman, P. Simmonds, 2013, Blood.

Incomplete sulphomucin-secreting intestinal metaplasia for gastric cancer. Preliminary data from a prospective study from three centres.

B. Gazzard, P. Dawson, B. Fabiani, 1985, Gut.

British HIV Association (BHIVA) guidelines for the treatment of HIV‐infected adults with antiretroviral therapy

B. Gazzard, C. Leen, M. Youle, 2003, HIV medicine.

Polymer coating of activated charcoal and its effects on biocompatibility and paracetamol binding.

E. H. Dunlop, B. Gazzard, R. Williams, 1974, Clinical science and molecular medicine.

Lamivudine in the Management of Adults with Human Immunodeficiency Virus Type 1 Infection

B. Gazzard, G. Moyle, 1998, Antiviral Therapy.

Summary of the international consensus symposium on management of HIV, CMV and hepatitis virus infections.

D. Richman, B. Gazzard, C. Katlama, 1998, Antiviral research.

Pharmacokinetics of saquinavir hard-gel/ritonavir and atazanavir when combined once daily in HIV Type 1-infected individuals administered different atazanavir doses.

B. Gazzard, M. Boffito, D. Back, 2006, AIDS research and human retroviruses.

Changes in sleep quality and brain wave patterns following initiation of an efavirenz‐containing triple antiretroviral regimen

B. Gazzard, C. Fletcher, G. Moyle, 2006, HIV medicine.

Biochemical assessment of pancreatic disease in human immunodeficiency virus infected men.

M. R. Hancock, B. Gazzard, D. Hawkins, 1997, Journal of clinical pathology.

Persistence of episomal HIV-1 infection intermediates in patients on highly active anti-retroviral therapy

John L. Sullivan, Thomas Greenough, Richard T. Ellison, 2000, Nature Medicine.

The cost of antiretroviral drugs and influence on prescribing policies

B. Gazzard, Rachael Jones, 2006, International journal of STD & AIDS.

Renal Dysfunction With Tenofovir Disoproxil Fumarate-Containing Highly Active Antiretroviral Therapy Regimens Is Not Observed More Frequently: A Cohort and Case-Control Study

B. Gazzard, M. Nelson, G. Moyle, 2004, Journal of acquired immune deficiency syndromes.

Penile ulcerations with foscarnet

B. Gazzard, M. Youle, G. Moyle, 1990, The Lancet.

British HIV Association (BHIVA) guidelines for the treatment of HIV‐infected adults with antiretroviral therapy (2005)

B. Gazzard, Bg Gazzard and, 2005, HIV medicine.

Hepatitis C infection is not associated with systemic HIV‐associated non‐hodgkin's lymphoma: A cohort study

B. Gazzard, L. Waters, M. Nelson, 2005, International journal of cancer.

Antiretroviral treatment regimens and immune parameters in the prevention of systemic AIDS-related non-Hodgkin's lymphoma.

B. Gazzard, M. Nelson, M. Bower, 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Responses to a 1 month self-report on adherence to antiretroviral therapy are consistent with electronic data and virological treatment outcome

Sundhiya Mandalia, Brian G Gazzard, B. Gazzard, 2002, AIDS.

Finding a Role for Zalcitabine in the HAART era

B. Gazzard, G. Moyle, 1998, Antiviral therapy.

The use and toxicity of didanosine (ddI) in HIV antibody-positive individuals intolerant to zidovudine (AZT)

B. Gazzard, D. Hawkins, G. Moyle, 1993, The Quarterly journal of medicine.

The steady-state pharmacokinetics of efavirenz and nevirapine when used in combination in human immunodeficiency virus type 1-infected persons.

B. Gazzard, J. Montaner, M. Youle, 2001, The Journal of infectious diseases.

Boosted saquinavir hard gel formulation exposure in HIV-infected subjects: ritonavir 100 mg once daily versus twice daily.

B. Gazzard, M. Boffito, D. Back, 2005, The Journal of antimicrobial chemotherapy.

Pharmacokinetics of saquinavir hard gel/ritonavir (1000/100 mg twice daily) when administered with tenofovir diproxil fumarate in HIV-1-infected subjects.

B. Gazzard, G. di Perri, M. Boffito, 2005, British journal of clinical pharmacology.

Steady-State Pharmacokinetics of Saquinavir Hard-Gel/Ritonavir/Fosamprenavir in HIV-1–Infected Patients

B. Gazzard, M. Boffito, D. Back, 2004, Journal of acquired immune deficiency syndromes.

Atazanavir enhances saquinavir hard-gel concentrations in a ritonavir-boosted once-daily regimen

B. Gazzard, M. Kurowski, M. Boffito, 2004, AIDS.

Pharmacokinetics of Once-Daily Saquinavir/Ritonavir in HIV-Infected Subjects: Comparison with the Standard Twice-Daily Regimen

B. Gazzard, M. Boffito, D. Back, 2003, Antiviral therapy.

Plasma and Intracellular Pharmacokinetics of Darunavir/Ritonavir Once Daily and Raltegravir Once and Twice Daily in HIV-Infected Individuals

B. Gazzard, S. Khoo, N. Liptrott, 2011, Journal of acquired immune deficiency syndromes.

Antiretroviral effect and safety of abacavir alone and in combination with zidovudine in HIV‐infected adults

R. Schooley, B. Gazzard, M. Saag, 1998, AIDS.

Foscarnet and Ganciclovir in the treatment of CMV retinitis in AIDS patients: a randomised comparison.

B. Gazzard, C. Harman, G. Moyle, 1992, The Journal of infection.

UvA-DARE ( Digital Academic Repository ) Nevirapine and Efavirenz Elicit Different Changes in Lipid Profiles in Antiretroviral-Therapy-Naive Patients Infected with HIV-1

B. Gazzard, C. Katlama, P. Reiss, 2017 .

Tenofovir Disoproxil Fumarate, Emtricitabine, and Efavirenz Versus Fixed-Dose Zidovudine/Lamivudine and Efavirenz in Antiretroviral-Naive Patients: Virologic, Immunologic, and Morphologic Changes-A 96-Week Analysis

B. Gazzard, J. Gallant, J. Arribas, 2006, Journal of acquired immune deficiency syndromes.

Nevirapine and Efavirenz Elicit Different Changes in Lipid Profiles in Antiretroviral- Therapy-Naive Patients Infected with HIV-1

B. Gazzard, F. van Leth, C. Katlama, 2004, PLoS medicine.

UvA-DARE ( Digital Academic Repository ) Nevirapine and Efavirenz Elicit Different Changes in Lipid Profiles in Antiretroviral-Therapy-Naive Patients Infected with HIV

B. Gazzard, C. Katlama, P. Reiss, 2004 .

Simplification to rilpivirine/emtricitabine/tenofovir disoproxil fumarate from ritonavir-boosted protease inhibitor antiretroviral therapy in a randomized trial of HIV-1 RNA-suppressed participants

B. Gazzard, K. White, J. van Lunzen, 2014, AIDS.

Better maintained adherence on switching from twice‐daily to once‐daily therapy for HIV: a 24‐week randomized trial of treatment simplification using stavudine prolonged‐release capsules

B. Gazzard, B. Gazzard, S. Portsmouth, 2005, HIV medicine.

Tenofovir, Emtricitabine Intracellular and Plasma, and Efavirenz Plasma Concentration Decay Following Drug Intake Cessation: Implications for HIV Treatment and Prevention

David Back, Victoria Watson, B. Gazzard, 2013, Journal of acquired immune deficiency syndromes.

Characterization of HIV-1 strains isolated from patients treated with TIBO R82913.

B. Gazzard, R. Pauwels, M. Youle, 1994, AIDS research and human retroviruses.

Increasing survival in AIDS patients with cytomegalovirus retinitis treated with combination antiretroviral therapy including HIV protease inhibitors

B. Gazzard, J. Walsh, E. Barnes, 1998, AIDS.

Foscarnet or ganciclovir for treatment of AIDS and CMV retinitis.

B. Gazzard, G. Moyle, 1995, The American journal of medicine.

Fixed drug eruption due to foscarnet.

B. Gazzard, D. Hawkins, G. M. Connolly, 1990, Genitourinary medicine.

Emtricitabine intolerance in treatment-experienced patients switched from lamivudine: a method of assessing toxicity.

B. Gazzard, M. Bower, M. Nelson, 2006, The Journal of antimicrobial chemotherapy.

Patient preferences for characteristics of antiretroviral therapies: results from five European countries

B. Gazzard, M. Murray, Shehzad Ali, 2014, Journal of the International AIDS Society.

Antiretroviral Therapy for HIV Infection

B. Gazzard, J. Gatell, D. Cooper, 1998, Drugs.

Transient elastography, liver stiffness values, and acute hepatopathy

B. Gazzard, M. Nelson, G. Panos, 2008, Hepatology.

Tenofovir Disoproxil Fumarate, Emtricitabine, and Efavirenz Compared With Zidovudine/Lamivudine and Efavirenz in Treatment-Naive Patients: 144-Week Analysis

B. Gazzard, J. Gallant, J. Arribas, 2008, Journal of acquired immune deficiency syndromes.

Associations between baseline characteristics, CD4 cell count response and virological failure on first-line efavirenz + tenofovir + emtricitabine for HIV

B. Gazzard, C. Leen, C. Fraser, 2019, Journal of virus eradication.

Discordant responses on starting highly active antiretroviral therapy: suboptimal CD4 increases despite early viral suppression in the UK Collaborative HIV Cohort (UK CHIC) Study *

B. Gazzard, C. Leen, D. Pillay, 2010, HIV medicine.

Predictors of CD4 count change over 8 months of follow up in HIV‐1‐infected patients with a CD4 count≥300 cells/μL who were assigned to 7.5 MIU interleukin‐2

B. Gazzard, F. Antunes, Z. Fox, 2007, HIV medicine.

Which nucleoside and nucleotide backbone combinations select for the K65R mutation in HIV-1 reverse transcriptase

B. Gazzard, D. Pillay, A. Winston, 2004, AIDS.

Increasing burden of liver disease in patients with HIV infection

B. Gazzard, D. Dieterich, K. Agarwal, 2011, The Lancet.

Identification of Kaposi's Sarcoma-Associated Herpesvirus (KSHV)-Specific Cytotoxic T-Lymphocyte Epitopes and Evaluation of Reconstitution of KSHV-Specific Responses in Human Immunodeficiency Virus Type 1-Infected Patients Receiving Highly Active Antiretroviral Therapy

B. Gazzard, C. Boshoff, V. Calvez, 2002, Journal of Virology.

CLINICAL FINDINGS AND SEROLOGICAL EVIDENCE OF HTLV-III INFECTION IN HOMOSEXUAL CONTACTS OF PATIENTS WITH AIDS AND PERSISTENT GENERALISED LYMPHADENOPATHY IN LONDON

B. Gazzard, C. Farthing, A. Dalgleish, 1984, The Lancet.

Phosphonoformate (foscarnet): a pilot study in AIDS and AIDS related complex.

B. Gazzard, C. Farthing, A. Dalgleish, 1987, AIDS.

Hyperlactataemia and lactic acidosis during antiretroviral therapy: relevance, reproducibility and possible risk factors

B. Gazzard, G. Moyle, S. Mandalia, 2002, AIDS.

An open-label assessment of TMC 125—a new, next-generation NNRTI, for 7 days in HIV-1 infected individuals with NNRTI resistance

B. Gazzard, S. Staszewski, A. Pozniak, 2003, AIDS.

Efficacy of 400 mg efavirenz versus standard 600 mg dose in HIV-infected, antiretroviral-naive adults (ENCORE1): a randomised, double-blind, placebo-controlled, non-inferiority trial

B. Gazzard, D. Cooper, P. Phanuphak, 2014, The Lancet.

Pharmacokinetics and Absolute Bioavailability of Oral Foscarnet in Human Immunodeficiency Virus-Seropositive Patients

B. Gazzard, M. Youle, S. Martin-Munley, 1998, Antimicrobial Agents and Chemotherapy.

A multicentre cohort experience with double-boosted protease inhibitors.

B. Gazzard, G. Koh, M. Nelson, 2009, The Journal of antimicrobial chemotherapy.

Pharmacokinetics of Atazanavir/Ritonavir Once Daily and Lopinavir/Ritonavir Twice and once Daily over 72 h following drug Cessation

B. Gazzard, S. Khoo, M. Boffito, 2008, Antiviral therapy.

Ritonavir-boosted atazanavir exposure is associated with an increased rate of renal stones compared with efavirenz, ritonavir-boosted lopinavir and ritonavir-boosted darunavir

B. Gazzard, M. Nelson, M. Bower, 2011, AIDS.

A randomized study comparing a three- and four-drug HAART regimen in first-line therapy (QUAD study).

B. Gazzard, M. Johnson, C. Orkin, 2005, The Journal of antimicrobial chemotherapy.

Treatment for adult HIV infection: 2004 recommendations of the International AIDS Society-USA Panel.

S. Hammer, D. Katzenstein, R. Schooley, 2004, JAMA.

Effects of First-Line Use of Nucleoside Analogues, Efavirenz, and Ritonavir-Boosted Protease Inhibitors on Lipid Levels

B. Gazzard, A. Hill, W. Sawyer, 2009 .

Gynaecomastia without lipodystrophy in HIV-1-seropositive patients on efavirenz: an alternative hypothesis.

B. Gazzard, D. King, M. Nelson, 2002, AIDS.

HIV/AIDS pathogenesis and treatment options focusing on the viral entry inhibitors

B. Gazzard, Rachael Jones, 2006, Expert review of anti-infective therapy.

Treatment and Prophylaxis of Pneumocystis carinii Pneumonia in AIDS Patients

B. Gazzard, Don E. Smith, 1991, Drugs.

Pseudomonas septicaemia associated with HIV.

B. Gazzard, D. Hawkins, D. Shanson, 1991, AIDS.

Matched case–control study to evaluate risk factors for hyperlactataemia in HIV patients on antiretroviral therapy

B. Gazzard, S. Mandalia, G. Moyle, 2003, HIV medicine.

The role of stavudine in the management of adults with HIV infection.

B. Gazzard, G. Moyle, 1997, Antiviral therapy.

Effect of terbutaline on bronchoconstriction induced by nebulised pentamidine.

B. Gazzard, J. Wiggins, J. Collins, 1991, Thorax.

Lack of response of anal intra-epithelial neoplasia to highly active antiretroviral therapy.

B. Gazzard, A. Winston, M. Bower, 2003, AIDS.

British HIV Association (BHIVA) guidelines for the treatment of HIV‐infected adults with antiretroviral therapy (2005)

B. Gazzard, 2005 .

Dose escalation or immediate full dose when switching from efavirenz to nevirapine-based highly active antiretroviral therapy in HIV-1-infected individuals?

B. Gazzard, A. Winston, D. Back, 2004, AIDS.

Hyperbilirubinemia and Pharmacokinetics and Zinc Sulfate: Impact on Coadministration of Atazanavir-Ritonavir

B. Gazzard, M. Boffito, G. Moyle, 2014 .

Coadministration of Atazanavir-Ritonavir and Zinc Sulfate: Impact on Hyperbilirubinemia and Pharmacokinetics

B. Gazzard, M. Boffito, D. Back, 2013, Antimicrobial Agents and Chemotherapy.

Pharmacokinetics of Once-Daily Darunavir-Ritonavir and Atazanavir-Ritonavir over 72 Hours following Drug Cessation

B. Gazzard, S. Khoo, M. Boffito, 2011, Antimicrobial Agents and Chemotherapy.

Pharmacokinetics of plasma lopinavir/ritonavir following the administration of 400/100 mg, 200/150 mg and 200/50 mg twice daily in HIV-negative volunteers.

B. Gazzard, S. Khoo, S. Emery, 2011, The Journal of antimicrobial chemotherapy.

British HIV Association (BHIVA) guidelines for the treatment of HIV‐infected adults with antiretroviral therapy

B. Gazzard, C. Leen, D. Pillay, 2001, HIV medicine.

Prognostic significance of immune subset measurement in individuals with AIDS-associated Kaposi's sarcoma.

B. Gazzard, T. Powles, M. Nelson, 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A prognostic index for AIDS-associated Kaposi's sarcoma in the era of highly active antiretroviral therapy

B. Gazzard, T. Powles, M. Nelson, 2006, The Lancet.

Resolution of AIDS-related Castleman's Disease with Anti-CD20 Monoclonal Antibodies is Associated with Declining IL-6 and TNF-α Levels

B. Gazzard, C. Thirlwell, M. Nelson, 2004, Leukemia & lymphoma.

How does HAART lead to the resolution of Kaposi's sarcoma?

B. Gazzard, J. Stebbing, S. Portsmouth, 2003, The Journal of antimicrobial chemotherapy.

Disease-associated dendritic cells respond to disease-specific antigens through the common heat shock protein receptor.

B. Gazzard, P. Srivastava, M. Bower, 2003, Blood.

Monocyte-derived dendritic cells from HIV type 1-infected individuals show reduced ability to stimulate T cells and have altered production of interleukin (IL)-12 and IL-10.

B. Gazzard, P. Kelleher, F. Gotch, 2009, The Journal of infectious diseases.

Resin column perfusion with whole blood or plasma separated by the continuous flow celltrifuge.

E. H. Dunlop, B. Gazzard, R. Hughes, 1975, Clinical science and molecular medicine.

Risk of HIV transmission in discordant couples

Geoffrey P Garnett, B. Gazzard, G. Garnett, 2008, The Lancet.

Why do people use paracetamol for suicide?

B. Gazzard, M. Davis, R. Williams, 1976, British medical journal.

What we know so far.

B. Gazzard, B Gazzard, 1996, AIDS.

Alimentary tract andpancreas Oesophageal symptoms, their causes, treatment, and prognosis inpatients withtheacquired immunodeficiency syndrome

B. Gazzard, D. Hawkins, O. Husain, 1989 .

Enhanced T-Cell Maturation, Differentiation and Function in HIV-1-Infected Individuals after Growth Hormone and Highly Active Antiretroviral Therapy

B. Gazzard, G. Moyle, F. Gotch, 2004, Antiviral therapy.

B. Gazzard, T. Powles, P. Shah, 2003, AIDS.

Leptomeningeal disease in AIDS-related non-Hodgkin's lymphoma

B. Gazzard, C. Thirlwell, M. Nelson, 2003, AIDS.

Changes in acquired immunodeficiency syndrome-related lymphoma since the introduction of highly active antiretroviral therapy.

B. Gazzard, T. Powles, M. Bower, 2000, Blood.

Testing for HIV: concise guidance.

B. Gazzard, D. Pillay, T. Peto, 2009, Clinical medicine.

HIV antibody testing in the antenatal clinic: the views of the consumers.

J. Catalan, B. Gazzard, J. Meadows, 1993, Midwifery.

Testing for HIV in the antenatal clinic: the views of midwives.

J. Catalan, B. Gazzard, L. Sherr, 1992, AIDS care.

HIV and surgeons.

B. Gazzard, C. Wastell, 1990, BMJ.

A Prognostic Index for Systemic AIDS-Related Non-Hodgkin Lymphoma Treated in the Era of Highly Active Antiretroviral Therapy

B. Gazzard, T. Powles, C. Thirlwell, 2005, Annals of Internal Medicine.

Mucin secretion in inflammatory bowel disease: correlation with disease activity and dysplasia.

B. Gazzard, M. Filipe, M. Ehsanullah, 1982, Gut.

Morphological and mucus secretion criteria for differential diagnosis of solitary ulcer syndrome and non-specific proctitis.

B. Gazzard, M. Filipe, M. Ehsanullah, 1982, Journal of clinical pathology.

The Host Control of Lytic and Latent Infection with Human Herpesvirus–8

B. Gazzard, M. Bower, J. Stebbing, 2006, The Journal of infectious diseases.

HIV disease and the gastroenterologist.

B. Gazzard, 1988, Gut.

Invasive amoebic colitis in AIDS patients.

B. Gazzard, C. Collins, N. Francis, 1992, AIDS.

Long‐term survival in patients with advanced immunodeficiency

S J Pocock, B G Gazzard, B. Gazzard, 1997, AIDS.

Acute lumbosacral polyradiculopathy due to cytomegalovirus in advanced HIV disease: CSF findings in 17 patients.

B. Gazzard, J. Fox, R. Miller, 1996, Journal of neurology, neurosurgery, and psychiatry.

Aids-associated vacuolar myelopathy and tumor necrosis factor-alpha (TNFα)

B. Gazzard, R. Guiloff, S. V. Tan, 1996, Journal of Neurological Sciences.

The use of fresh frozen plasma or a concentrate of factor IX as replacement therapy before liver biopsy.

B. Gazzard, J. Henderson, R. Williams, 1975, Gut.

Coagulation factor concentrate in the treatment of the haemorrhagic diathesis offulminant hepatic failure 995 Prior to During treatment treatment

B. Gazzard, Roger Williams, C. Rizza, 2006 .

Coagulation factor concentrate in the treatment of the haemorrhagic diathesis of fulminant hepatic failure

B. Gazzard, C. Rizza, R. Williams, 1974, Gut.

New concepts in anti-HIV therapies

B. Gazzard, M. Bower, J. Stebbing, 2006, New Concepts of Antiviral Therapy.

Assessment of type 1 and type 2 cytokines in HIV type 1-infected individuals: impact of highly active antiretroviral therapy.

B. Gazzard, F. Gotch, N. Imami, 1999, AIDS research and human retroviruses.

Surrogate markers now provide physicians with the best means to manage antiretroviral therapy: The case for

B. Gazzard, G. Moyle, 1997, Genitourinary medicine.

HIV-1 Viral Replication below 50 Copies/ml in Patients on Antiretroviral Therapy is not associated with CD8+ T-cell Activation

B. Gazzard, P. Kelleher, M. Shamji, 2007, Antiviral therapy.

Transient Nature of Long-Term Nonprogression and Broad Virus-Specific Proliferative T-Cell Responses with Sustained Thymic Output in HIV-1 Controllers

B. Gazzard, M. Nelson, F. Gotch, 2009, PloS one.

Tetanus vaccination with IL-2 during highly active antiretroviral therapy induces sustained and pronounced specific CD4 T-cell responses

B. Gazzard, A. Sullivan, M. Nelson, 2004, AIDS.

Innate and adaptive immunological insights into HIV pathogenesis

B. Gazzard, H. Kandil, J. Stebbing, 2003, International journal of STD & AIDS.

CD8+/CD161++ mucosal-associated invariant T-cell levels in the colon are restored on lsong-term antiretroviral therapy and correlate with CD8+ T-cell immune activation

B. Gazzard, Rebecca Metcalf, L. Greathead, 2014, AIDS.

Safety and Immunogenicity of DNA Prime and Modified Vaccinia Ankara Virus-HIV Subtype C Vaccine Boost in Healthy Adults

B. Gazzard, G. Alter, M. Boffito, 2013, Clinical and Vaccine Immunology.

The Impact of Transmitted Drug-Resistance on Treatment Selection and Outcome of First-Line Highly Active Antiretroviral Therapy (HAART)

B. Gazzard, C. Sabin, A. Phillips, 2009, Journal of acquired immune deficiency syndromes.

Evidence of a decline in transmitted HIV-1 drug resistance in the United Kingdom

John P. Walsh, Andrew N. Phillips, Steve Kaye, 2007, AIDS.

A Risk-Benefit Assessment of HIV Protease Inhibitors

B. Gazzard, G. Moyle, 1999, Drug safety.

Detection of herpesvirus DNA by nested polymerase chain reaction in cerebrospinal fluid of human immunodeficiency virus-infected persons with neurologic disease: a prospective evaluation.

B. Gazzard, J. Fox, R. Miller, 1995, The Journal of infectious diseases.

Accumulation of DC-SIGN+CD40+ dendritic cells with reduced CD80 and CD86 expression in lymphoid tissue during acute HIV-1 infection

B. Gazzard, R. Weber, H. Stellbrink, 2002, AIDS.

Antibody-targeted MHC complex-directed expansion of HIV-1- and KSHV-specific CD8+ lymphocytes: a new approach to therapeutic vaccination.

B. Gazzard, G. Ogg, A. McMichael, 2004, Blood.

Mycobacterial immune reconstitution inflammatory syndrome in HIV-1 infection after antiretroviral therapy is associated with deregulated specific T-cell responses: Beneficial effect of IL-2 and GM-CSF immunotherapy

B. Gazzard, M. Nelson, F. Gotch, 2005, Journal of immune based therapies and vaccines.

Are previous treatment interruptions associated with higher viral rebound rates in patients with viral suppression?

B. Gazzard, C. Leen, D. Pillay, 2008, AIDS.

A dedicated clinic for HIV-positive individuals over 50 years of age: a multidisciplinary experience

B. Gazzard, B. Patterson, L. Waters, 2012, International journal of STD & AIDS.

Treatment switches after viral rebound in HIV-infected adults starting antiretroviral therapy: multicentre cohort study

David Dunn, Kholoud Porter, John Walsh, 2008, AIDS.

Efavirenz versus boosted atazanavir or zidovudine and abacavir in antiretroviral treatment-naive, HIV-infected subjects: week 48 data from the Altair study.

B. Gazzard, D. Cooper, C. Duncombe, 2010, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Effect of sputum induction on arterial oxygen saturation and spirometry in HIV-infected patients.

B. Gazzard, J. Collins, T. Leigh, 1994, The European respiratory journal.

Outcomes in the First Year after Initiation of First-Line Haart among Heterosexual Men and Women in the Uk Chic Study

B. Gazzard, C. Leen, D. Pillay, 2011, Antiviral therapy.

A comparison of regimens based on non-nucleoside reverse transcriptase inhibitors or protease inhibitors in preventing Kaposi's sarcoma

B. Gazzard, M. Nelson, M. Bower, 2003, AIDS.

Changes in Cardiovascular Disease Risk Factors With Immediate Versus Deferred Antiretroviral Therapy Initiation Among HIV‐Positive Participants in the START (Strategic Timing of Antiretroviral Treatment) Trial

B. Gazzard, E. Soliman, A. Phillips, 2017, Journal of the American Heart Association.

Thyroid dysfunction and relationship to antiretroviral therapy in HIV-positive individuals in the HAART era.

B. Gazzard, T. Powles, M. Bower, 2009, Journal of acquired immune deficiency syndromes.

Does HIV disease progression influence epidermal Langerhans cell density?

B. Gazzard, D. Hawkins, S. Barton, 1996, The British journal of dermatology.

The Incidence of AIDS-De fi ning Illnesses at a Current CD 4 Count ≥ 200 Cells / μ L in the Post – Combination Antiretroviral Therapy Era

B. Gazzard, A. Mocroft, O. Kirk, 2013 .

Switch from inhibitory to activating NKG2 receptor expression in HIV-1 infection: lack of reversion with highly active antiretroviral therapy

B. Gazzard, M. Nelson, F. Gotch, 2005, AIDS (London).

Short communication: NKG2C+ NK cells contribute to increases in CD16+CD56- cells in HIV type 1+ individuals with high plasma viral load.

B. Gazzard, M. Bower, C. Mela, 2013, AIDS research and human retroviruses.

Patient tolerance of nebulized pentamidine or cotrimoxazole as secondary prophylaxis for Pneumocystis carinii pneumonia.

B. Gazzard, D. Smith, D. Hills, 1992, AIDS (London).

A long-term durable remission with high-dose therapy and autologous stem cell transplant for stage IVB HIV-associated Hodgkins disease

B. Gazzard, A. Chaidos, M. Nelson, 2008, AIDS.

Triple-class antiretroviral agent resistance in a large cohort: prevalence and clinical outcomes.

B. Gazzard, T. Powles, M. Bower, 2008, Archives of internal medicine.

Changes in Outcome of Persons Initiating Highly Active Antiretroviral Therapy at a CD4 Count Less Than 50 Cells/mm3

B. Gazzard, C. Leen, C. Sabin, 2008, Journal of acquired immune deficiency syndromes.

The effect of HAART in 254 consecutive patients with AIDS-related Kaposi's sarcoma

B. Gazzard, M. Boffito, M. Nelson, 2009, AIDS.

Megestrol Acetate Vs Cyproheptadine in the Treatment of Weight Loss Associated with HIV Infection

J. Catalan, B. Gazzard, M. Youle, 1992, International journal of STD & AIDS.

Feasibility and Effectiveness of Indicator Condition-Guided Testing for HIV: Results from HIDES I (HIV Indicator Diseases across Europe Study)

Stefan Esser, Josip Begovac, Jens D. Lundgren, 2013, PloS one.

Surgical management of anorectal disease in HIV‐positive homosexuals

C. H. Mellor, B. Gazzard, T. Allen-Mersh, 1990, The British journal of surgery.

Efficacy of a Nelfinavir- and Nevirapine-Containing Salvage Regimen

B. Gazzard, A. Sullivan, G. Moyle, 2000, HIV clinical trials.

Abdominal pain in HIV infection.

A. Forbes, B. Gazzard, P. Thuluvath, 1991, The Quarterly journal of medicine.

Inflammatory bowel disease in individuals seropositive for the human immunodeficiency virus

B. Gazzard, D. Sharpstone, A. Duggal, 1996, European journal of gastroenterology & hepatology.

Long term probability of detection of HIV-1 drug resistance after starting antiretroviral therapy in routine clinical practice

B. Gazzard, D. Pillay, C. Sabin, 2005, AIDS.

Pharmacokinetics and Safety of Etravirine Administered Once or Twice Daily After 2 Weeks Treatment With Efavirenz in Healthy Volunteers

B. Gazzard, L. Waters, M. Boffito, 2009, Journal of acquired immune deficiency syndromes.

Tuberculosis presenting as inflammatory bowel disease

B. Gazzard, M. Filipe, A. Isaacs, 1984, Diseases of the colon and rectum.

Elevated plasma lipopolysaccharide is not sufficient to drive natural killer cell activation in HIV-1-infected individuals

B. Gazzard, M. Bower, F. Gotch, 2009, AIDS.

Development and application of a new measure of engagement in out‐patient HIV care

B. Gazzard, C. Leen, D. Pillay, 2016, HIV Medicine.

Erythrocyte glutathione deficiency in symptom-free HIV infection is associated with decreased synthesis rate.

B. Gazzard, D. Sharpstone, W. Heird, 1999, American journal of physiology. Endocrinology and metabolism.

Voluntary HIV testing in the antenatal clinic: differing uptake rates for individual counselling midwives.

J. Catalan, B. Gazzard, J. Meadows, 1990, AIDS care.

The picture of future therapy.

B. Gazzard, 1999, International journal of clinical practice. Supplement.

ACUTE ILLNESSES ASSOCIATED WITH HTLV-III SEROCONVERSION

B. Gazzard, C. Farthing, 1985, The Lancet.

PREVALENCE OF ANTIBODY TO HUMAN T-LYMPHOTROPIC VIRUS TYPE III IN AIDS AND AIDS-RISK PATIENTS IN BRITAIN

E. M. Briggs, D. Jeffries, B. Gazzard, 1984, The Lancet.

Risk of HIV dementia and opportunistic brain disease in AIDS and zidovudine therapy

J. Catalan, B. Gazzard, T. Baldeweg, 1998, Journal of neurology, neurosurgery, and psychiatry.

International Congress of Drug Therapy in HIV Infection 2‐6 November 2014, Glasgow, UK

Samit R. Joshi, Charlene A Flash, Thomas Lengauer, 2014 .

A phase I, randomized study of combined IL-2 and therapeutic immunisation with antiretroviral therapy

B. Gazzard, R. Moss, A. Sullivan, 2007, Journal of immune based therapies and vaccines.

Determination of Clinically Relevant Cutoffs for HIV-1 Phenotypic Resistance Estimates Through a Combined Analysis of Clinical Trial and Cohort Data

S. Hammer, B. Gazzard, L. Bacheler, 2008, Journal of acquired immune deficiency syndromes.

No change to HIV-1 latency with valproate therapy.

B. Gazzard, S. Shaunak, P. Kelleher, 2006, AIDS.

Cytomegalovirus colitis in AIDS: plain abdominal radiograph findings.

B. Gazzard, C. D. Collins, J. Gleeson, 1993, Clinical radiology.

A Balanced Type 1/Type 2 Response Is Associated with Long-Term Nonprogressive Human Immunodeficiency Virus Type 1 Infection

B. Gazzard, F. Gotch, N. Imami, 2002, Journal of Virology.

Prospective HLA-B*5701 screening and abacavir hypersensitivity: a single centre experience

Sundhiya Mandalia, B. Gazzard, L. Waters, 2007, AIDS.

Interleukin-2-associated viral breakthroughs induce HIV-1-specific CD4 T cell responses in patients on fully suppressive highly active antiretroviral therapy.

B. Gazzard, A. Sullivan, M. Nelson, 2003, AIDS.

The risks and incidence of K65R and L74V mutations and subsequent virologic responses.

B. Gazzard, T. Powles, L. Waters, 2008, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

of Pneumocystis carinii pneumonia . immunofluorescence staining for diagnosis DNA amplification by PCR with Quantitative and qualitative comparison of

B. Gazzard, J. Collins, A. Rowbottom, 2004 .

Adherence to trizivir and tenofovir as a simplified salvage regimen is associated with suppression of viraemia and a decreased cholesterol.

B. Gazzard, M. Nelson, C. Michailidis, 2005, The Journal of antimicrobial chemotherapy.

Induction therapy with Trizivir plus Efavirenz: Time study (AZL 30004) results at 24 weeks.

B. Gazzard, J. Rockstroh, A. Castagna, 2003 .

The prevalence and determinants of the K65R mutation in HIV-1 reverse transcriptase in tenofovir-naive patients.

B. Gazzard, D. Pillay, A. Winston, 2002, AIDS.

Successful treatment of acute haemorrhagic cytomegalovirus colitis with ganciclovir in an individual without overt immunocompromise

B. Gazzard, J. Andreyev, M. Pickering, 2003, European journal of gastroenterology & hepatology.

infected individuals - Conservation of unique cell-surface CD antigen mosaics in HIV-1

David P. Kreil, W. Gilks, B. Gazzard, 2013 .

HIV-1-infected individuals Conservation of unique cell-surface CD antigen mosaics in

David P. Kreil, W. Gilks, B. Gazzard, 2010 .

Conservation of unique cell-surface CD antigen mosaics in HIV-1-infected individuals.

David P. Kreil, W. Gilks, B. Gazzard, 2005, Blood.

All for CD91 and CD91 for all.

B. Gazzard, S. Patterson, J. Stebbing, 2003, The Journal of antimicrobial chemotherapy.

Guillain--Barre syndrome following immune reconstitution after antiretroviral therapy for primary HIV infection.

B. Gazzard, R. Jones, M. Nelson, 2007, Journal of HIV therapy.

Highly active antiretroviral therapy and human immunodeficiency virus-associated primary cerebral lymphoma.

B. Gazzard, T. Powles, M. Nelson, 2006, Journal of the National Cancer Institute.

Treatment outcome in presumed and confirmed AIDS-related primary cerebral lymphoma.

B. Gazzard, K. Fife, M. Nelson, 1999, European journal of cancer.

The management of meningeal lymphoma in patients with HIV in the era of HAART: intrathecal depot cytarabine is effective and safe.

B. Gazzard, M. Nelson, M. Bower, 2006, Blood.

A case of march fracture in a patient with osteoporosis on long-term HAART

B. Gazzard, M. Nelson, S. F. Forsyth, 2002, International journal of STD & AIDS.

Cryptosporidial diarrhoea inAIDSandits treatment

B. Gazzard, D. Shanson, M. Dryden, 1988 .

Foscarnet-induced changes in plasma concentrations of total and ionized calcium and magnesium in HIV-positive patients.

B. Gazzard, M. Youle, A. Lant, 1996, Antiviral therapy.

A retrospective study of neutropenia in HIV disease

B. Gazzard, D. Moore, A. Sullivan, 2000, International journal of STD & AIDS.

Controlling the HIV Epidemic with Antiretrovirals

B. Gazzard, S. McCormack, H. Rees, 2013, Journal of the International Association of Providers of AIDS Care.

biopsy . replacement therapy before liver concentrate of factor IX as The use of fresh frozen plasma or a

B. Gazzard, J. Henderson, Roger Williams, 2022 .

Auditing HIV Testing Rates across Europe: Results from the HIDES 2 Study

A. Grzeszczuk, M. L. Jakobsen, J. Minton, 2015, PloS one.

Uptake and Outcome of Combination Antiretroviral Therapy in Men Who Have Sex with Men According to Ethnic Group: The UK CHIC Study

B. Gazzard, C. Leen, C. Sabin, 2011, Journal of acquired immune deficiency syndromes.

VHRM_5206_De Lorenzo.indd

B. Gazzard, M. Boffito, S. Collot-Teixeira, 2009 .

Progression of whole blood transcriptional signatures from interferon-induced to neutrophil-associated patterns in patients with severe influenza

J. Banchereau, B. Gazzard, D. Chaussabel, 2018, Nature Immunology.

Virological suppression at 6 months is related to choice of initial regimen in antiretroviral-naive patients: a cohort study

B. Gazzard, C. Sabin, A. Phillips, 2002, AIDS.

A predictive model of health state utilities for HIV patients in the modern era of highly active antiretroviral therapy.

Josephine Mauskopf, B. Gazzard, J. Mauskopf, 2008, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.

The Impact of Patient, Disease, and Treatment-Related Factors on Quality of Life for HIV Patients on HAART

B. Gazzard, J. Mauskopf, A. Shearer, 2006 .

New strategies for lowering the costs of antiretroviral treatment and care for people with HIV/AIDS in the United Kingdom

B. Gazzard, A. Hill, C. Moecklinghoff, 2012, ClinicoEconomics and outcomes research : CEOR.

Steatorrhoea in the elderly.

B. Gazzard, A. Dawson, H. Price, 1977, British medical journal.

BASHH/EAGA position statement on the HIV window period

B. Gazzard, D. Webster, L. Waters, 2015, International journal of STD & AIDS.

Use of Viral Load Measured After 4 Weeks of Highly Active Antiretroviral Therapy to Predict Virologic Outcome at 24 Weeks for HIV-1–Positive Individuals

Caroline A Sabin, Schlomo Staszewski, B. Gazzard, 2004, Journal of acquired immune deficiency syndromes.

Identification of two mutually exclusive groups after long-term monitoring of HIV DNA 2-LTR circle copy number in patients on HAART

B. Gazzard, J. Choi, S. Shaunak, 2003, AIDS (London).

Incidence of cancer in individuals receiving chronic zopiclone or eszopiclone requires prospective study.

B. Gazzard, L. Waters, M. Bower, 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Restoration of Human Immunodeficiency Virus‐1‐Specific Responses in Patients Changing from Protease to Non‐Nucleoside Reverse Transcriptase Inhibitor‐Based Antiretroviral Therapy

B. Gazzard, A. Sullivan, G. Moyle, 2003, Scandinavian journal of immunology.

Safety of intravitreous fomivirsen for treatment of cytomegalovirus retinitis in patients with AIDS.

B. Gazzard, R. Danis, S. Lightman, 2002, American journal of ophthalmology.

Impact of NNRTI compared to PI‐based highly active antiretroviral therapy on CCR5 receptor expression, β ‐chemokines and IL‐16 secretion in HIV‐1 infection

B. Gazzard, F. Gotch, N. Imami, 2002, Clinical and experimental immunology.

Author Correction: Progression of whole-blood transcriptional signatures from interferon-induced to neutrophil-associated patterns in severe influenza

J. Banchereau, B. Gazzard, D. Chaussabel, 2019, Nature Immunology.

The heat-shock protein receptor CD91 is up-regulated in monocytes of HIV-1-infected "true" long-term nonprogressors.

B. Gazzard, P. Srivastava, S. Shaunak, 2003, Blood.

The relationship of psychological variables and disease progression among long-term HIV-infected men

J. Catalan, B. Gazzard, P. Easterbrook, 2000, International journal of STD & AIDS.

Treatment exhaustion of highly active antiretroviral therapy (HAART) among individuals infected with HIV in the United Kingdom: multicentre cohort study

B. Gazzard, C. Sabin, P. Easterbrook, 2005, BMJ : British Medical Journal.

CD4 cell count and initiation of antiretroviral therapy: trends in seven UK centres, 1997–2003

B. Gazzard, R. Gilson, C. Sabin, 2007, HIV medicine.

The frequency and reasons for antiretroviral switching with specific antiretroviral associations: the SWITCH study.

B. Gazzard, M. Nelson, M. Bower, 2010, Antiviral research.

Acute glandular fever‐like illness in a patient with HTLV‐III antibody

B. Gazzard, A. Zuckerman, B. Gazzard, 1985, Journal of medical virology.

Rate of CD4 cell decline and prediction of survival in zidovudine-treated patients.

B. Gazzard, P. Easterbrook, J. Emami, 1993, AIDS.

Therapy for herpes simplex virus with emphasis on the role of foscarnet

B. Gazzard, S. Barton, 1993 .

Use of antidepressants and risk of cancer in individuals infected with HIV.

B. Gazzard, T. Powles, M. Bower, 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

HIV AND SURGEONS : THE RISKS ARE SMALL

B. Gazzard, C. Wastell, 1990 .

Protease inhibitors potentiate chemotherapy-induced neutropenia.

B. Gazzard, N. Ryan, M. Nelson, 2004, Blood.

Randomized dose-comparison studies of intravitreous fomivirsen for treatment of cytomegalovirus retinitis that has reactivated or is persistently active despite other therapies in patients with AIDS.

B. Gazzard, R. Danis, S. Lightman, 2002, American journal of ophthalmology.

Does less frequent routine monitoring of patients on a stable, fully suppressed cART regimen lead to an increased risk of treatment failure?

B. Gazzard, A. Mocroft, O. Kirk, 2008, AIDS.

Increased duration of viral suppression is associated with lower viral rebound rates in patients with previous treatment failures

B. Gazzard, C. Sabin, P. Easterbrook, 2007, AIDS.

The rate of viral rebound after attainment of an HIV load <50 copies/mL according to specific antiretroviral drugs in use: results from a multicenter cohort study.

B. Gazzard, C. Sabin, P. Easterbrook, 2005, The Journal of infectious diseases.

An open-label randomized clinical trial of novel therapeutic strategies for HIV-infected patients in whom antiretroviral therapy has failed: rationale and design of the OPTIMA Trial.

J. Singer, B. Gazzard, M. Youle, 2003, Controlled clinical trials.

Virologic rebound on HAART in the context of low treatment adherence is associated with a low prevalence of antiretroviral drug resistance.

B. Gazzard, A. Pozniak, M. Nelson, 2002 .

Comparison of virologic, immunologic, and clinical response to five different initial protease inhibitor-containing and nevirapine-containing regimens.

B. Gazzard, P. Easterbrook, R. Newson, 2001 .

Switching to zidovudine plus lamivudine plus abacavir maintains viral suppression in patients with high viral load before antiretroviral therapy: a retrospective clinical cohort analysis.

B. Gazzard, G. Moyle, 2002, AIDS.

The diagnostic yield of stool analysis in 525 HIV-1-infected individuals.

B. Gazzard, J. Stebbing, Debasis Datta, 2003, AIDS.

Pharmacokinetics and antiretroviral response to darunavir/ritonavir and etravirine combination in patients with high-level viral resistance

B. Gazzard, A. Winston, M. Boffito, 2007, AIDS.

Absence of association between individual thymidine analogues or nonnucleoside analogues and lipid abnormalities in HIV-1-infected persons on initial therapy.

B. Gazzard, M. Nelson, G. Moyle, 2000, Journal of acquired immune deficiency syndromes.

Kingdom: multicentre cohort study individuals infected with HIV in the United antiretroviral therapy (HAART) among Treatment exhaustion of highly active

B. Gazzard, C. Sabin, P. Easterbrook, 2008 .

Antiretroviral therapy CNS penetration and HIV-1–associated CNS disease

B. Gazzard, C. Leen, D. Pillay, 2011, Neurology.

Sialomucins in the assessment of dysplasia and cancer‐risk patients with ulcerative colitis treated with colectomy and ileo‐rectal anastomosis

B. Gazzard, M. Filipe, M. Ehsanullah, 1985, Histopathology.

Delayed Gastric Emptying in Human Immunodeficiency Virus Infection

B. Gazzard, K. Nijran, D. Wingate, 2000, Digestive Diseases and Sciences.

Studies on the allostimulatory function of dendritic cells from HCV-HIV-1 co-infected patients

B. Gazzard, R. Glassman, M. Nelson, 2004, Cell Research.

Developments in HIV medicine

B. Gazzard, M. Nelson, Rachael Jones, 2007 .

Evidence of thymic reconstitution after highly active antiretroviral therapy in HIV‐1 infection

B. Gazzard, P. Hayes, R. Aspinall, 2004, HIV medicine.

Thymic output during initial highly active antiretroviral therapy (HAART) and during HAART supplementation with interleukin 2 and/or with HIV type 1 immunogen (Remune).

B. Gazzard, A. Sullivan, F. Gotch, 2003, AIDS research and human retroviruses.

AIDS surveillance: a direct assessment of under-reporting

B. Gazzard, M. Hickman, J. Aldous, 1993, AIDS.

Progression of whole-blood transcriptional signatures from interferon-induced to neutrophil-associated patterns in severe influenza

J. Banchereau, B. Gazzard, D. Chaussabel, 2018, Nature Immunology.

Low levels of perforin expression in CD8+ T lymphocyte granules in lymphoid tissue during acute human immunodeficiency virus type 1 infection.

B. Gazzard, H. Stellbrink, L. Perrin, 2002, The Journal of infectious diseases.

The efficacy of lopinavir in individuals experiencing protease inhibitor failure.

B. Gazzard, Y. Gilleece, A. Pozniak, 2003, Journal of acquired immune deficiency syndromes.

A randomized trial to investigate the recycling of stavudine and didanosine with and without hydroxyurea in salvage therapy (RESTART).

B. Gazzard, C. Orkin, A. Pozniak, 2004, The Journal of antimicrobial chemotherapy.

The natural history and clinical significance of intermittent viraemia in patients with initial viral suppression to < 400 copies/ml

Brian G Gazzard, B. Gazzard, P. Easterbrook, 2002, AIDS.

The SENSE trial: etravirine shows lower prevalence and severity of neuropsychiatric adverse events compared to efavirenz in treatment-naïve patients

B. Gazzard, S. Esser, S. Rugină, 2010, Journal of the International AIDS Society.

AIDS and the health professions

D. Jeffries, G. Ridgway, B. Gazzard, 1985, British medical journal.

The Influence of the M184V Mutation in HIV-1 Reverse Transcriptase on the Virological Outcome of Highly Active Antiretroviral Therapy Regimens with Or without Didanosine

B. Gazzard, N. Graham, A. Pozniak, 2005, Antiviral Therapy.

2021 update to HIV-TRePS: a highly flexible and accurate system for the prediction of treatment response from incomplete baseline information in different healthcare settings.

B. Gazzard, R. Kaiser, B. Larder, 2021, The Journal of antimicrobial chemotherapy.

2018 update to the HIV-TRePS system: the development of new computational models to predict HIV treatment outcomes, with or without a genotype, with enhanced usability for low-income settings

Dechao Wang, Shanmugam Saravanan, John Baxter, 2018, The Journal of antimicrobial chemotherapy.

Treatment Outcome and Cost-Effectiveness of Different Highly Active Antiretroviral Therapy Regimens in the Uk (1996–2002)

B. Gazzard, R. Brettle, M. Youle, 2008, International journal of STD & AIDS.

The efficacy of ritonavir in the prevention of AIDS‐related Kaposi's sarcoma

B. Gazzard, C. Brock, M. Nelson, 2004, International journal of cancer.

Burkitt's lymphoma and previous AIDS-defining illnesses are not prognostic factors in AIDS-related non-Hodgkin's lymphoma.

B. Gazzard, C. Palmieri, M. Bower, 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

First-in-Human Evaluation of the Safety and Immunogenicity of an Intranasally Administered Replication-Competent Sendai Virus–Vectored HIV Type 1 Gag Vaccine: Induction of Potent T-Cell or Antibody Responses in Prime-Boost Regimens

B. Gazzard, E. Karita, O. Anzala, 2016, The Journal of infectious diseases.

Dietary advice with or without pravastatin for the management of hypercholesterolaemia associated with protease inhibitor therapy

B. Gazzard, G. Moyle, Brian G. Gazzard, 2001, AIDS.

Clinical Features and Outcome in HIV-Associated Multicentric Castleman's Disease.

B. Gazzard, K. Naresh, M. Nelson, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Persistent Ulceration of the Anal Margin in Homosexuals with Hiv Infection

B. Gazzard, D. Hawkins, T. Allen-Mersh, 1991, Journal of the Royal Society of Medicine.

Rising rates of HIV infection

B. Gazzard, A. Robinson, 2005, BMJ : British Medical Journal.

Use of electron microscopy in examination of faeces and rectal and jejunal biopsy specimens.

B. Gazzard, J. Williams, D. Ellis, 1991, Journal of clinical pathology.

The value of barium enema and colonoscopy in patients infected with HIV.

A. Forbes, B. Gazzard, J. Gleeson, 1990, AIDS.

30 years of HIV: what have we learned?

B. Gazzard, 2014, Journal of the International AIDS Society.

Polymerase chain reaction evidence for human immunodeficiency virus 1 neutralization by passive immunization in patients with AIDS and AIDS-related complex.

B. Gazzard, I. Hewlett, A. Karpas, 1990, Proceedings of the National Academy of Sciences of the United States of America.

The Effect of Statins on HIV Rebound and Blips

B. Gazzard, L. Waters, M. Bower, 2005, Journal of acquired immune deficiency syndromes.

Virological failure and development of new resistance mutations according to CD4 count at combination antiretroviral therapy initiation

B. Gazzard, D. Webster, C. Leen, 2015, HIV medicine.

by simple outpatient assessments . pneumonia in HIV antibody positive patients Diagnosis of Pneumocystis carinii

A. Forbes, B. Gazzard, Don E. Smith, 2022 .

Clinical investigations of lymphadenopathy, including lymph node biopsies, in 24 homosexual men with antibodies to the human T‐cell lymphotropic virus type III (HTLV‐III)

B. Gazzard, C. Farthing, K. Henry, 1986, The British journal of surgery.

A comparison of several agents with two delivery systems for the prevention of airway narrowing induced by nebulised pentamidine isethionate.

B. Gazzard, J. Wiggins, J. Collins, 1991, Respiratory medicine.

Measuring human T cell responses in blood and gut samples using qualified methods suitable for evaluation of HIV vaccine candidates in clinical trials.

Frances Gotch, Peter Kelleher, Ambreen Ashraf, 2011, Journal of immunological methods.

Emergency laparotomy in patients with AIDS

W. W. Slack, B. Gazzard, R. Miller, 1991, The British journal of surgery.

Does discordancy between the CD4 count and CD4 percentage in HIV-positive individuals influence outcomes on highly active antiretroviral therapy?

B. Gazzard, C. Leen, D. Pillay, 2012, The Journal of infectious diseases.

To sequence or not to sequence?

B. Gazzard, G. Moyle, 1997, Expert opinion on investigational drugs.

Predictors of loss of virologic response in subjects who simplified to lopinavir/ritonavir monotherapy from lopinavir/ritonavir plus zidovudine/lamivudine.

B. Gazzard, M. King, C. Hicks, 2009, AIDS research and human retroviruses.

Virological failure and subsequent resistance profiles in individuals exposed to atazanavir

B. Gazzard, T. Powles, M. Bower, 2007, AIDS (London).

Are Long-Term Non-Progressors Very Slow Progressors? Insights from the Chelsea and Westminster HIV Cohort, 1988–2010

B. Gazzard, E. Beck, M. Nelson, 2012, PloS one.

Blind comparison of Abbott and Dupont HIV antigen ELISA tests for detecting antigenaemia in asymptomatic human immunodeficiency virus antibody positive homosexual men.

B. Gazzard, K. Brown, A. Coates, 1990, Journal of clinical pathology.

Cardiac autonomic dysfunction in AIDS is not secondary to heart failure.

P. Ponikowski, B. Gazzard, A. Coats, 2000, International journal of cardiology.

Plasma IL-6 as a marker of mycobacterial immune restoration disease in HIV-1 infection.

B. Gazzard, C. Orkin, N. Imami, 2003, AIDS.

Fibreoptic bronchoscopy indiagnosis of bronchopulmonary Kaposi's sarcoma

B. Gazzard, P. Hanson, J. Collins, 1987 .

Non‐uptake of highly active antiretroviral therapy among patients with a CD4 count < 350 cells/μL in the UK

B. Gazzard, C. Leen, J. Ainsworth, 2012, HIV medicine.

Tuberculosis, HIV and the developing world.

B. Gazzard, 2001, Clinical medicine.

Improving the evidence for indicator condition guided HIV testing in Europe: Results from the HIDES II Study – 2012 – 2015

B. Gazzard, A. Mocroft, A. d’Arminio Monforte, 2019, PloS one.

Initiation of Antiretroviral Therapy During Recent HIV-1 Infection Results in Lower Residual Viral Reservoirs

B. Gazzard, F. Gotch, N. Imami, 2004, Journal of acquired immune deficiency syndromes.

Recovery of the human immunodeficiency virus from fibreoptic bronchoscopes.

D. Jeffries, B. Gazzard, M. Chadwick, 1991, Thorax.

Preoperative HIV Antibody Testing: The Views of Surgeons and Patients

J. Catalan, B. Gazzard, G. Irving, 1995, International journal of STD & AIDS.

Comparison of two cohorts of patients presenting with AIDS: patients with previously known HIV diagnoses and true late presenters

B. Gazzard, M. Rayment, A. Scourfield, 2013, Sexually Transmitted Infections.

T-cell signalling in antiretroviral-treated, aviraemic HIV-1-positive individuals is present in a raised state of basal activation that contributes to T-cell hyporesponsiveness

B. Gazzard, G. Moyle, M. Attaf, 2011, AIDS.

Women and HIV infection: investigation of its psychosocial consequences.

J. Catalan, B. Gazzard, A. Burgess, 1996, Journal of psychosomatic research.

Progressive CD4 cell depletion and death in zidovudine-treated patients.

B. Gazzard, P. Easterbrook, J. Emami, 1993, Journal of acquired immune deficiency syndromes.

Comparison of metabolic abnormalities 48 weeks after switching from highly active antiretroviral therapy containing a non-nucleoside reverse transcriptase inhibitor to Trizivir versus continued highly active antiretroviral therapy

B. Gazzard, M. Moroni, C. Katlama, 2003, AIDS (London).

Stemming the HIV epidemic: prevention and therapy go hand in hand.

B. Gazzard, J. Stebbing, 2003, Journal of HIV therapy.

HAART PROLONGS TIME TO TREATMENT FAILURE (TTF) IN KAPOSI'S SARCOMA (KS).

B. Gazzard, K. Fife, M. Bower, 1999 .

The radiological appearances of bone lymphoma in AIDS.

B. Gazzard, A. Banerjee, T. Marshall, 1992, Clinical radiology.

R211K and L214F do not invariably confer high level phenotypic resistance to thymidine analogs in zidovudine-naive patients with M184V.

B. Gazzard, K. Hertogs, Y. Gilleece, 2001, Journal of acquired immune deficiency syndromes.

Positive and Negative drug Selection Pressures on the N348I Connection Domain Mutation: New Insights from in vivo Data

David Dunn, Huw Price, Deenan Pillay, 2010, Antiviral therapy.

Virus host interactions

B. Gazzard, J. Stebbing, 2003 .

The role of HIV-proteinase inhibitors.

B. Gazzard, G. Moyle, 1996, Genitourinary medicine.

When should asymptomatic patients with HIV infection be treated with zidovudine?

B. Gazzard, 1992, BMJ.

Current Knowledge and Future Prospects for the Use of HIV Protease Inhibitors

B. Gazzard, G. Moyle, 1996, Drugs.

Marked hypertriglyceridaemia associated with ritonavir therapy [letter]

Feher, B. Gazzard, A. Sullivan, 1998 .

Delayed gastric emptying in human immunodeficiency virus infection: correlation with symptoms, autonomic function, and intestinal motility.

B. Gazzard, K. Nijran, E. Yazaki, 2000, Digestive Diseases and Sciences.

Predictors of virological outcome and safety in primary HIV type 1-infected patients initiating quadruple antiretroviral therapy: QUEST GW PROB3005.

B. Gazzard, J. Montaner, R. Weber, 2007, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

The Value of Screening HIV-Infected Individuals for Didanosine-Related Liver Disease?

B. Gazzard, L. Waters, M. Nelson, 2011, Antiviral therapy.

Rising Population Cost for Treating People Living with HIV in the UK, 1997-2013

B. Gazzard, R. Brettle, M. Youle, 2010, PloS one.

A World of HIV Treatment Experience Freely Available at the Click of a Mouse

B. Gazzard, A. Revell, H. Lane, 2014 .

HIV DNA two long terminal repeat circles: observations and interpretations.

B. Gazzard, J. Choi, S. Shaunak, 2003, AIDS.

J. Catalan, B. Gazzard, L. Leonidou, 2014, AIDS care.

Artificial liver support based on haemoperfusion of adsorbents.

R Williams, E. H. Dunlop, E H Dunlop, 1975, Biomedical engineering.

Effects of age on antiretroviral plasma drug concentration in HIV-infected subjects undergoing routine therapeutic drug monitoring.

B. Gazzard, C. Leen, A. Winston, 2013, The Journal of antimicrobial chemotherapy.

Chronic Kidney Disease Risk in African and Caribbean Populations With HIV

B. Gazzard, C. Leen, D. Pillay, 2018, The Journal of infectious diseases.

Low frequency of genotypic resistance in HIV-1-infected patients failing an atazanavir-containing regimen: a clinical cohort study

B. Gazzard, D. Webster, C. Leen, 2013, The Journal of antimicrobial chemotherapy.

Opportunistic protozoan diarrhoea.

B. Gazzard, F. Awad-El-Kariem, Y. Miao, 2002, Journal of HIV therapy.

Expression of PD-L1, a marker of disease status, is not reduced by HAART in aviraemic patients

B. Gazzard, M. Nelson, F. Gotch, 2007, AIDS.

Weight loss caused by a thalamic astrocytoma

B. Gazzard, J. M. Goldman, 1984, Gut.

An Open-Label, Randomized Comparative Pilot Study of a Single-Class Quadruple Therapy Regimen versus a 2–Class Triple Therapy Regimen for Individuals Initiating Antiretroviral Therapy

Martin Fisher, Sundhiya Mandalia, B. Gazzard, 2006, Antiviral therapy.

Maternal HIV infection

J. Catalan, B. Gazzard, J. Meadows, 1991, The Lancet.

"I plan to have the HIV test"--predictors of testing intention in women attending a London antenatal clinic.

J. Catalan, B. Gazzard, J. Meadows, 1993, AIDS care.

Protection of rats against the hepatotoxic effect of paracetamol.

B. Gazzard, R. Hughes, R. Williams, 1974, British journal of experimental pathology.

Early prediction oftheoutcome ofaparacetamol overdose based onananalysis of163patients

B. Gazzard, R. Hughes, B. Widdop, 1977 .

The Use of Cysteamine and Dimercaprol

B. Gazzard, R. Hughes, I. Murray-Lyon, 1976, Journal of International Medical Research.

An outbreak of methicillin-resistant Staphylococcus aureus (MRSA) infection in HIV-seropositive persons

B. Azadian, B. Gazzard, B. Gazzard, 1998, International journal of STD & AIDS.

Penile ulceration with foscarnet therapy.

B. Gazzard, S. Barton, G. Moyle, 1993, AIDS.

Antiretroviral therapy with or without protease inhibitors impairs postprandial TAG hydrolysis in HIV-infected men

B. Gazzard, S. Wootton, G. Moyle, 2009, British Journal of Nutrition.

Increased proportion of CD16+ NK cells in the colonic lamina propria of inflammatory bowel disease patients, but not after azathioprine treatment

M. Altfeld, B. Gazzard, G. Nuovo, 2010, Alimentary pharmacology & therapeutics.

Salvage therapy with abacavir plus efavirenz or nevirapine in HIV-1-infected persons with previous nucleoside analogue and protease inhibitor use.

B. Gazzard, C. Leen, A. Cheesbrough, 2000, AIDS.

Preventing HIV infection

B. Gazzard, Y. Halima, Rachael Jones, 2005, British medical journal.

Data linkage reduces loss to follow-up in an observational HIV cohort study.

B. Gazzard, C. Leen, A. Winston, 2010, Journal of clinical epidemiology.

Natural killer cells are not infected by Kaposi's sarcoma-associated herpesvirus in vivo, and natural killer cell counts do not correlate with the risk of developing Kaposi's sarcoma

B. Gazzard, M. Bower, S. Mandalia, 2003, AIDS.

Prior fluconazole exposure as an independent risk factor for fluconazole resistant candidosis in HIV positive patients: a case-control study.

B. Gazzard, J. Midgley, J. Cartledge, 1997, Genitourinary medicine.

The effectiveness of indicator disease-based HIV testing across Europe - results from a prospective multi-centre study

M. Jakobsen, B. Gazzard, A. Mocroft, 2015 .

Eflornithine versus cotrimoxazole in the treatment of Pneumocystis carinii pneumonia in AIDS patients

B. Gazzard, D. Smith, B. Gazzard, 1992, AIDS.

Serum nitrite concentration suggests a role for nitric oxide in AIDS.

J. Catalan, B. Gazzard, T. Baldeweg, 1996, AIDS (London).

Assessing the role of peripheral CD8 T cells in neurocognitive impairment in HIV-infected men who have sex with men: data from the MSM Neurocog Study

B. Gazzard, A. Pozniak, S. Mandalia, 2015, International journal of STD & AIDS.

Different methods to calculate the inhibitory quotient of boosted single protease inhibitors and their association with virological response.

B. Gazzard, A. Winston, S. Khoo, 2006, Journal of acquired immune deficiency syndromes.

Clinical utility of resistance testing.

B. Gazzard, J. Stebbing, 2002, Journal of HIV therapy.

Abnormalities of Liver Function during HIV Seroconversion Illness

B. Gazzard, D. Hawkins, B. Gazzard, 1992, International journal of STD & AIDS.

Outcome in AIDS-Related Systemic Non-Hodgkin Lymphoma and Leptomeningeal Disease Is Not Predicted by a CT Brain Scan

B. Gazzard, T. Powles, M. Nelson, 2007, American Journal of Neuroradiology.

CHANGES IN AIDS‐RELATED LYMPHOMA SINCE THE INTRODUCTION OF HAART: ABSTRACT 47

B. Gazzard, T. Powles, M. Bower, 2000 .

Energy balance in asymptomatic HIV infection

B. Gazzard, D. Sharpstone, H. Ross, 1996, AIDS.

Neurological Presentations of AIDS-when to Test for HIV

B. Gazzard, F. Scaravilli, G. Fuller, 1989, Journal of the Royal Society of Medicine.

The impact of HIV drug resistance testing on changes to treatment

B. Gazzard, C. Sabin, A. Phillips, 2011, AIDS.

Pharmacokinetics and safety of the co-administration of the antiretroviral raltegravir and the lipid-lowering drug ezetimibe in healthy volunteers.

B. Gazzard, M. Boffito, D. Back, 2011, The Journal of antimicrobial chemotherapy.

Factors influencing lopinavir and atazanavir plasma concentration.

B. Gazzard, C. Leen, D. Pillay, 2010, The Journal of antimicrobial chemotherapy.

Improvements in all-cause mortality across Europe 2002-2007 and regional Differences in incidence of HIV/AIDS and non HIV/AIDS death across Europe

B. Gazzard, A. Mocroft, O. Kirk, 2009 .

Investigation of low-dose ritonavir on human peripheral blood mononuclear cells using gene expression whole genome microarrays.

B. Gazzard, L. Waters, M. Boffito, 2010, Genomics.

A Meta-analysis of Transient Elastography for the Detection of Hepatic Fibrosis

B. Gazzard, L. Jiao, M. Nelson, 2010, Journal of clinical gastroenterology.

Pharmacokinetics of Atazanavir/Ritonavir Once Daily and Lopinavir/Ritonavir Twice and once Daily over 72 h following drug Cessation

B. Gazzard, S. Khoo, M. Boffito, 2008, Antiviral therapy.

B. Gazzard, 1984 .

The metabolic response to opportunistic infections in AIDS

B. Gazzard, D. Sharpstone, H. Ross, 1996, AIDS.

Frequency of multinucleoside analogue-resistant genotypes observed during antiretroviral therapy.

B. Gazzard, G. Moyle, A. Basar, 2000, AIDS (London).

Attempted immune stimulation in the "gay compromise syndrome".

B. Gazzard, S. Fisher-Hoch, G. Oswald, 1982, British medical journal.

Treatment exhaustion of highly active antiretroviral therapy (HAART) among individuals infected with HIV in the United Kingdom: multicentre cohort study

B. Gazzard, C. Sabin, P. Easterbrook, 2005, BMJ : British Medical Journal.

A predictive model of health state utilities for HIV patients in the modern era of highly active antiretroviral therapy.

B. Gazzard, J. Mauskopf, A. Shearer, 2008, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.

Use of electron microscopy in examination of faeces and rectal and jejunal biopsy specimens.

B. Gazzard, J. Williams, D. Ellis, 1991, Journal of clinical pathology.

Journal of Immune Based Therapies and Vaccines Mycobacterial Immune Reconstitution Inflammatory Syndrome in Hiv-1 Infection after Antiretroviral Therapy Is Associated with Deregulated Specific T-cell Responses: Beneficial Effect of Il-2 and Gm-csf Immunotherapy Immune Reconstitutiont Cellshiv-1mycob

B. Gazzard, F. Gotch, N. Imami, 2022 .

Factor VIII levels during the course of acute hepatitis in a haemophiliac.

B. Gazzard, R. Williams, P. Flute, 1975, Journal of clinical pathology.

Mucin secretion in inflammatory bowel disease: correlation with disease activity and dysplasia.

B. Gazzard, M. Ehsanullah, Isabel Filipe, 1982, Gut.

Weight loss caused by a thalamic astrocytoma

B. Gazzard, J. M. Goldman, 1984, Gut.

Hepatitis C virus reinfection incidence and treatment outcome among HIV-positive MSM

B. Gazzard, P. Vickerman, M. Hickman, 2013, AIDS (London).

Opportunistic Infections in HIV Seropositive Individuals

B. Gazzard, 1995, Journal of the Royal College of Physicians of London.

Autoimmune hepatitis caused by Brucella: causal or a mere association?

B. Gazzard, J. Stebbing, 2003, International journal of clinical practice.

Effects of First-Line Use of Nucleoside Analogues, Efavirenz, and Ritonavir-Boosted Protease Inhibitors on Lipid Levels

B. Gazzard, A. Hill, W. Sawyer, 2009, HIV clinical trials.

Monocyte-derived dendritic cells from HIV type 1-infected individuals show reduced ability to stimulate T cells and have altered production of interleukin (IL)-12 and IL-10.

B. Gazzard, P. Kelleher, F. Gotch, 2009, The Journal of infectious diseases.